Home

BioAge Labs, Inc. - Common Stock (BIOA)

4.8100
+0.0300 (0.63%)

BioAge Labs is a biotechnology company focused on leveraging artificial intelligence and machine learning to unlock the biology of aging and develop therapeutics that can extend healthy lifespan

The company harnesses its proprietary platform to analyze vast amounts of biological data in order to identify and validate novel drug targets linked to aging-related diseases. Through its innovative research, BioAge aims to create effective therapies that not only treat age-associated conditions but also improve overall health and longevity in individuals.

SummaryNewsPress ReleasesChartHistoricalFAQ
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 9, 2024
Crude Oil Gains 2%; BioAge Labs Shares Plungebenzinga.com
Via Benzinga · December 9, 2024
Nasdaq Down Over 100 Points; US Wholesale Inventories Rise By 0.2%benzinga.com
Via Benzinga · December 9, 2024
Tesla To $370? Here Are 10 Top Analyst Forecasts For Mondaybenzinga.com
Via Benzinga · December 9, 2024
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 9, 2024
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concernsbenzinga.com
BioAge Labs halts STRIDES Phase 2 trial of azelaprag after liver enzyme elevations, plans further analysis with updates expected in Q1 2025.
Via Benzinga · December 9, 2024
Why Interpublic Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · December 9, 2024
Self-Driving Startup Pony.ai Files For U.S. IPOtalkmarkets.com
Self-driving startup Pony.ai of China filed for an IPO in the U.S. this week. Meanwhile, four companies -- Springview Holdings, Oriental Rise Holdings, PTL Limited, and Samfine Creation Holdings Group -- saw their stocks open for trading.
Via Talk Markets · October 20, 2024
Prediction: These 2 Stocks Could Soar in 2025fool.com
The key word here is "could."
Via The Motley Fool · October 17, 2024
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boomfool.com
The future of the weight loss market might not revolve around GLP-1 drugs.
Via The Motley Fool · October 13, 2024
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stockfool.com
BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.
Via The Motley Fool · October 12, 2024
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Nowfool.com
One of these businesses is a risky play, but the other is very likely to succeed.
Via The Motley Fool · October 7, 2024
3 Reasons to Buy BioAge Labs Stock Hand Over Fist in Octoberfool.com
There's a chance that its lead candidate could become one of the top drugs ever.
Via The Motley Fool · October 5, 2024
This IPO Biotech Stock Could Be the Next Eli Lillyfool.com
BioAge has its eyes on a handful of truly gargantuan markets.
Via The Motley Fool · October 3, 2024
Obesity Drug Developer BioAge Makes Nasdaq Debuttalkmarkets.com
Shares of BioAge Labs opened for trading this week, with the company planning to use the proceeds of its initial public offering to take its lead obesity drug further into clinical trials.
Via Talk Markets · September 29, 2024
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPOinvestors.com
The company is working on a drug that mimics apelin, which is released following exercise.
Via Investor's Business Daily · September 26, 2024